Diabetes

Study calls for action to help adolescents with diabetes transition to adult care

Study calls for action to help adolescents with diabetes transition to adult care
Dr. Meranda Nakhla is the lead author of a study, which was published in BMJ Open Diabetes Research & Care, that calls for action to help adolescents with diabetes transition to adult care. Credit: McGill University Health Centre

Adolescence can be a turbulent period of life, with struggles to establish autonomy, identity issues and risk-taking behaviours. For young adults with a chronic illness such as type 1 diabetes, this transition phase also brings about other challenges as they assume an increased responsibility for their overall health. A new study from the Research Institute of the McGill University Health Centre (RI-MUHC) sheds light on gaps in transition care practice in Quebec, pointing out a lack of standardized policies across pediatric diabetes centres. These findings, which were published in the open-access journal BMJ Open Diabetes Research & Care, highlight a need for the evaluation and development of targeted interventions at multiple levels to improve the transition process.

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA (sofosbuvir/velpatisvir). HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

  • If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, and adverse reactions to RBV also apply. Refer to RBV prescribing information.
  • Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.
  • The most common adverse reactions (≥10%, all grades) with EPCLUSA were headache and fatigue; and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.
  • Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.
  • Coadministration of EPCLUSA…